We remain committed to providing assistance to those living with or at risk of HIV. At this time, we do not anticipate making changes to any of the Advancing Access support offerings or co-pay coupon programs for our other HIV medications.
Gilead is committed to ensuring that our medications are available to all who need them and believes people should be able to work together with their healthcare provider to determine the most appropriate HIV prevention or treatment strategy for them. With a few exceptions due to state laws regarding generic medicines (see below), qualified individuals will currently continue to receive assistance for Atripla, Truvada and Descovy under the Advancing Access patient support offerings and co-pay coupon programs. Gilead Remains Committed to Maintaining Advancing Access® Program for HIV Prevention and Treatment Medicinesįoster City, Calif., Septem– Gilead has received questions from the HIV community regarding the status of our Advancing Access support plans for individuals currently using Atripla®, Truvada® or Descovy®, following the loss of exclusivity for Atripla and Truvada in the United States.
0 kommentar(er)
